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ABSTRAK
Tujuan: untuk melaporkan perubahan-perubahan parameter hemostasis, misalnya agregasi trombosit, 
viskositas darah dan plasma, waktu protrombin, APTT, CRP, dan fibrinogen sebelum dan sesudah pemberian 
terapi sel punca. Metode: terdapat 24 pasien yang ikut serta dalam penelitian ini. PBSCs dipanen dan disuntikkan 
ke arteri yang berhubungan dengan infark (infarct-related artery) setelah pemberian G-CSF selama 5 hari 
berturut-turut. Rekombinan eritropoietin manusia/recombinant human erythropoietin diberikan pada saat 
penyuntikan PBSCs intrakoroner dilakukan. Hasil: kami dapat melakukan evaluasi pada 11 dari 24 pasien 
tentang status hemostasis pra- dan pasca-suntikan sel punca. Tidak ada perbedaan yang bermakna antara data 
dasar dan 3 bulan kemudian dalam hal aggregasi spontan (p=0,350), PT (p=0,793), aPTT (p=0,255) dan TT 
(p=0,254). Juga tidak ada perbedaan bermakna antara data dasar dan 3 bulan kemudian dalam hal viskositas 
plasma (p=0,442) dan viskositas darah (p=0,843). Meskipun demikian, pasien yang memiliki viskositas darah 
dan plasma di atas atau di bawah kisaran normal nilai laboratorium belum kembali ke titik normal setelah 
perlakuan. Baik PT maupun APTT, keduanya menunjukkan nilai normal. Kadar fibrinogen dan CRP menunjukkan 
penurunan yang bermakna antara data dasar dan 3 bulan setelah pengobatan, masing-masing dengan nilai 
p=0,009 dan p=0,04. Kesimpulan: kombinasi G-CSF dan EPO based-intracoronary infusion dari PBSCs dapat 
membuka perspektif baru dalam pengobatan keadaan hiperkoagulabilitas pasca infark miokardium akut/AMI.
Kata kunci: koagulasi, agregasi trombosit, infark miokardium, hiperkoagulasi.
ABSTRACT
Aim: to investigate hemostatic parameter changes, such as platelet aggregation, blood and plasma 
viscosity, prothrombin time, APTT, CRP and fibrinogen, before and after administration of stem cell therapy.   
Methods: a total of 24 patients were enrolled. Peripheral blood stem cells (PBSCs) were harvested and 
injected into the infarct-related artery after 5 consecutive days of G-CSF administration. Recombinant human 
erythropoietin was administered at the time of intracoronary PBSCs injection. Results: we were able to evaluate Vol 46 • Number 1 • January 2014                                  Hemostatic status of pre and post intracoronary injection
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INTRODUCTION
Cardiovascular disease has increased in the 
last half century, becoming one of the major 
causes of morbidity in all hospital admissions. 
Hypertension and coronary heart disease (CHD) 
constitute a major bulk of these CVD cases, 
where myocardial infarction (MI) constitutes half 
of all CHD cases.1 In 2008, 1 of 6 deaths in United 
States was caused by coronary heart disease.2 
Current guidelines emphasize acute myocardial 
infarction (AMI) therapy on early coronary 
reperfusion that alleviates mortality rates such 
as primary percutaneous coronary intervention 
(PCI) or thrombolytic therapy. However, these 
conventional therapy sometimes cannot reverse 
the damage to infarcted myocardium.1,3
Virchow in 1856 postulated a triad of 
predisposition to thrombus formation. These 
triads are abnormalities of blood flow, blood 
constituents, and vessel wall. Abnormal 
elevation, even one of these factors, predispose to 
a “prothrombotic” or “hypercoagulable” state.4,5 
Population of patients with AMI showed these 
state very clearly. Even those undergoing optimal 
treatment procedure are still at risk for further 
ischemic events not only because procedure-
related platelet activation occurs, but also due 
to the persistent platelet hyperreactivity and 
enhanced thrombin generation associated with 
ACS.6,7 Hyperreactivity of platelets was shown 
in TIMI 12 trial up to 28 days and PREPARE 
trial in up to 6 months.8-10 It is not known how 
the acute coronary thrombosis alter the kinetics 
of the systemic coagulation system. There are 
some theory proposed like increased activity 
of fIX and decreased fII and fV, elevated fVII 
antigen and coagulant activity.11
Latest researches has highlighted stem cell 
therapy for patient population at risk for heart 
failure. Recent meta-analysis showed adult 
stem cell have shown significant, safety and 
favourable impact in treating heart failure and 
myocardial infarction.3,12-15 G-CSF-based stem 
cell therapy has been proposed as a practical 
and non-invasive alternative to stem cell therapy 
using bone marrow stem cells.16 G-CSF might 
be considered mostly as a mobilizer to enrich 
peripheral blood stem cells (PBSCs). Despite the 
potential adverse effects of increasing vascular 
events, short term use of G-CSF in patients with 
AMI seems to be safe. 
In 2008, we published an article showing 
18 patients with anterior ST-segment elevation 
AMI, which showed improvement in most of 
the cardiac functions after injection of peripheral 
blood stem cells (PBSCs) into the infarct-related 
artery.3 With the same protocol we are able 
to evaluate 6 more patients further regarding 
pre- and post- treatment (3 months) hemostatic 
profile such as platelet aggregation, blood and 
plasma viscosity, prothrombin time, APTT, CRP 
and fibrinogen. The purpose of this study is to 
investigate hemostasic parameter changes before 
and after administration of stem cell therapy.
METHODS
We enrolled 24 patients diagnosed with 
ST-segment elevation anterior wall infarction 
who had successful PCI with drug-eluting stent 
implantation and were referred late (more than 2 
hours) to our hospital but still within 15 days after 
onset of symptom. None of the patients received 
fibrinolytic therapy. PCI was performed regardless 
of the patients’ hemodynamic condition. Other 
11 from 24 of patients regarding hemostatic status pre–post stem cell injection. There were no significant 
difference between baseline vs 3 months in spontaneous aggregation (p=0.350), PT (p=0.793), aPTT (p=0.255) 
and TT (p=0.254). There were also no significant difference between baseline vs 3 months in plasma viscosity 
(p=0.442) and blood viscosity (p=0.843). Nevertheless the patient who had their blood and plasma viscosity 
above or below normal laboratory range return to normal level after the treatment. Both PT and APTT also 
show normalization value. Both Fibrinogen and CRP level show significant decrease between baseline and 3 
months after treatment (p=0.009) and (p=0.04) respectively. Conclusion: combined G-CSF and EPO based-
intracoronary infusion of PBSCs may open new perspective in the treatment of hypercoagulable state post AMI.
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inclusion criteria were as follows: age 20 years 
or over and subject’s willingness to comply with 
specific follow-up evaluations. All patients had 
complete revascularization even in non-infarct 
related territory. Exclusion criteria were: 1). 
hemodynamic instability during the procedure or 
any condition that may put the patient at undue 
risk such as pulmonary edema and cardiogenic 
shock, 2). previous or current severe co-existing 
diseases, such as cancer, hematological disorders 
(Hb <10 g/dL, WBC <4 or >11x109/L, or platelets 
<100x109/L), renal failure (creatinine level >2.5 
mg/dL, or creatinine clearance <30 cc/min), 
hepatic dysfunction, serious infection or any co-
morbidities that may impact patients’ survival), 
3). valvular heart disease and prosthetic valves, 
4). hypertrophic or restrictive cardiomyopathy, 
5). women of child bearing potential, and 6). lack 
of informed consent.
The study was conducted in accordance with 
the declaration of Helsinki and was approved 
by the University of Indonesia Medical School 
Ethical Committee. All patients gave written 
informed consent.
Study Protocol 
One-to-three days after PCI, a daily dose 
of 10 μg/kg/day of G-CSF (Lenograstim 
[GranocyteTM], Aventis-Sanofi)) was 
administered subcutaneously for 5 consecutive 
days. CD34+ and CD 45+ cells were quantified 
at days 1 (baseline), 3, and 5 after injection and 
subsequently the peripheral blood stem cells 
(PBSCs) were harvested. A total of 150 ml of 
PBSCs was processed from the brachial vein 
using COBE Spectra and placed into a peripheral 
blood (PB) unfiltered collection bag (Baxter 
Health Care Corp, IL), which was discarded 
after PB infusion. CD34+ and CD 45+ cells 
enumeration was performed using FACSCalibur 
(Becton Dickinson).
To ensure sterility of the harvesting procedure, 
the white cell concentrate was cultured for 
bacteria and fungi. Three milliliters of the cell 
concentrate was injected into BacT Alert PF 
Pediatric tube (Biomerieux Inc, Durham, NC, 
cat No. 259794) and the incubated in the BacT 
Alert 120 system (Organon Teknika, Durham, 
NC) for 7 days or until the culture become 
positive. The cell concentrate was also cultured 
on Sabouraud agar medium (Oxoid, cat No. CM 
0041) for fungi.
Patients were heparinized during stem cell 
injection. Cells were injected with the use of 
a stop flow technique through an over the wire 
balloon catheter positioned within the segment 
containing of the stent. The balloon was inflated 
with low pressure to completely block the 
blood flow for 3 min, during which time 5-6 
ml PBSC suspension was injected. This was 
interrupted by 3 min of reflow by deflating the 
balloon to minimize the likelihood of extensive 
ischemia. After completion of intracoronary 
cell transplantation, coronary angiography 
was repeated to ascertain vessel patency and 
absence of capillary plugging by measuring the 
myocardial blush grade. Approximately 15-25 x 
106 PBSCs were injected during each procedure. 
All (except one) patients received subcutaneous 
4000 IU of recombinant human erythropoietin 
(EprexTM) and glycoprotein IIb/IIIa inhibitors 
(IntergrellinTM) intravenous bolus and infusion 
at the time of intracoronary PBSCs injection. 
Patients were discharged the day after. Unless 
there was contraindication, all patients also 
received optimal standard therapy including 
aspirin, clopidogrel, nitrates, b-blockers, ACE-
inhibitor/angiotensin-receptor blockers and 
statins. 
The additional parameter compared in this 
study were PT, APTT, TT, platelet aggregation, 
blood and plasma viscosity, fibrinogen and 
CRP. All parameters were checked before and 3 
months after treatment.
RESULTS
Almost all patients were male in gender 
and most of them were at the age of 50-59. The 
common ACS risk factors existed in the patient 
were dyslipidemia (52%), smoking (42%), and 
family history (25%).
Table 2 shows platelet aggregation from 
all patients before and after treatment of cell-
therapy. No significant difference between 
baseline and 3 months after in spontaneous 
aggregation (3.11%+0.02% vs 5.39%+0.07%; 
p=0.350).Vol 46 • Number 1 • January 2014                                  Hemostatic status of pre and post intracoronary injection
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No significant difference between baseline 
and after 3 months treatment in plasma viscosity 
(1.64+0.14% vs 1.63+0.07%; p=0.442) and 
blood viscosity (8.06 +1.70 vs 7.56+0.83%; 
p=0.843). On the other hand fibrinogen and 
CRP level showed significant decrease between 
baseline and 3 months after treatment (575+165 
Table 1. Patient’s characteristics
Criteria n (%)
Age Group
  - 40-49 2 (8.0)
  - 50-59 16 (67.0)
  - 60-69 6 (25.0)
Sex
  - Male 23 (96.0)
  - Female 1 (4.0)
History
  - Hypertension 4 (17.0)
  - Diabetes 3 (13.0)
  - Dyslipidemia 13 (54.0)
  - Smoking 10 (42.0)
  - Obesity 5 (21.0)
  - Family 6 (25.0)
Blood test
  - Ureum >40 mg/dl (n=19) 5 (26.0)
  - Creatinin >1.5 mg/dl (n=19) 0 (0)
  - Total Cholesterol >200 mg/dl (n=18) 7 (39.0)
  - HDL <50 mg/dl (n=18) 16 (89.0)
  - LDL >150 mg/dl (n=18) 4 (22.0)
  - Uric Acid >7 mg/dl (n=15) 5 (33.0)
Table 2. Platelet aggregattion at baseline and after 3 months treatment
No.
Baseline 3 Months After PSCT
Spont Aggr  Aggre 5 Aggre 10 Spont Aggr  Aggre 5 Aggre 10
1 3.20% 2.30% 2.70% 6.40% 12.30% 9.10%
2 1.80% 10.00% 12.70% 3.20% 25.50% 35.90%
3 7.30% 10.00% 10.90% 4.10% 1.40% 4.50%
4 4.50% 4.50% 11.40% 4.10% 14.50% 13.20%
5 3.20% 10.90% 17.70% 3.60% 9.10% 20.50%
6 4.10% 57.30% 62.70% 0.90% 36.80% 47.30%
7 3.20% 21.40% 26.40% 1.40% 34.60% 45.00%
8 1.40% 50.90% 55.90% 3.60% 20.00% 32.30%
9 3.20% 8.60% 13.60% 5.60% 3.20% 12.90%
10 2.70% 19.80% 27.30% 1.10% 9.70% 15.00%
11 2.20% 5.80% 65.80% 3.10% 6.00% 8.00%
Mean+SD 3.35+0.02 18.32+0.10 27.92+0.23 3.37+0.02 15.74+0.12 22.15+0.15
 p value 0.969 0.570 0.408
vs 354+93; p=0.009) and (p=0.04) respectively.
Eventhough Table 2 shows no significant 
changes in blood and plasma viscosity, Figure 
1 show trends of normalization. The patients 
who had their blood and plasma viscosity above 
normal range returned to normal point after the 
treatment. The same thing observed in patient 
who have their viscosity below normal range, it 
elevated to normal range.
No significant difference in: PT (12.31+0.80 
vs 12.44+1.36; p=0.793), APTT (36.59+17.89 
vs 30.25+2.52; p=0.255) and TT (15.9+0.33 vs 
19.7 +7.52; p=0.254) at baseline and at 3 months 
after therapy. Both PT and APTT also show 
normalization value, as seen in Table 4.
DISCUSSION
Stem cell therapy is an intervention strategy 
that introduces adult stem cells into damaged 
tissue in order to treat disease or injury. Whereas 
stem cells are biological cells found in all 
multicellular organisms that can divide and 
differentiate into diverse specialized cell types 
and can self-renew to produce more stem cells. 
There are minimally 4 accessible source of adult 
stem cells in humans, bone marrow, adipose 
tissue, blood, and wharton jelly (umbilical 
cord).17-20
In this study we do an ad hoc analysis 
comparing hemostatic profile before and after 
injection of PBSC cell therapy. We emphasize the Cosphiadi Irawan                                                                                                     Acta Med Indones-Indones J Intern Med
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Figure 1. Normalization of blood and plasma viscosity at baseline and after 3 months of treatment
Table 4. PT-APTT-TT at baseline dan 3 months after treatment
PT APTT TT
Baseline After 3 Months Baseline After 3 Months No of patients Baseline After 3 months
12.4 11.5 25.4 29.5 1 15.4 16.1
13.4 11.9 89.9 32.1 2 15.9 16.6
10.9 11.3 29.7 28.2 3 16.1 19.3
13.3 12.2 32.1 29.6 4 15.8 16.6
11.9 12.5 29.8 31.6 5 15.9 15.0
13.0 12.1 31.7 28.9 6 16.4 34.8
11.3 12.0 32.2 26.7 Mean+SD 15.9+0.33 19.7+7.52
12.3 11.9 32.8 31.3
12.3 12.9 36.9 31.2
12.3 16.1 30.6 35.8
31.4 27.8
Table 3. Blood and plasma viscosity at baseline and after 3 months of therapy
No
Blood Viscosity Plasma Viscosity Fibrinogen (mg/dl) CRP
Baseline
After 3 
Months
Baseline
After 3 
Months
Baseline
After 3 
months
Baseline
After 3 
months
1 6.85 6.74 1.47 1.55 377 314 20,1 4
2 7.66 6.10 1.53 1.72 937 352 6,9 17,1
3 8.24 7.26 1.70 1.69 458 454 103,1 0,01
4 9.77 7.49 1.76 1.71 680 282 40,4 20,1
5 11.02 7.52 1.76 1.59 552 321 85,3 0,8
6 5.60 8.24 1.66 1.61 446 352 1,5 0,01
7 7.77 7.32 1.87 1.64 570 504 20 1,86
8 9.54 7.31 1.55 1.59 478 468 53,68 6,05
9 7.50 7.50 1.68 1.69 726 218 8,47 13,92
10 5.64 9.07 1.43 1.53 530 276 191,94 1,63
11 9.05 8.63 1.58 1.59 575.4 354.1 53.139 6.548
mean+SD 8.06+1.70 7.56+0.83 1.64+0.14 1.63+0.07Vol 46 • Number 1 • January 2014                                  Hemostatic status of pre and post intracoronary injection
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use of G-CSF as a mobilizer to enrich PBSCs. 
From 24 patients, most of them are males. The 
3 most common risk factors associated with 
ACS are dyslipidemia, smoking, and family 
history which exist in 54%, 42%, and 25% of the 
patients. All patients in this study receive heparin 
until 3 days after intervention, and afterwards the 
treatments are continued with standard optimal 
therapy as indicated.
From 24 patients, we are able to follow 
11 patients regarding the hemostatic profile. 
As shown in table 2-4 there are no significant 
difference between platelet aggregation, blood 
and plasma viscosity, PT, APTT, and TT pre- and 
post- treatment. However, surprising result can 
be seen in Figure 1. There are 8 patients who 
have increased blood viscosity and 3 patients 
with increased plasma viscosity before treatment 
who return to normal laboratory range after 
treatment. On the other side, there are 2 patients 
with decreased blood viscosity and 4 patients 
who have decreased plasma viscosity before 
treatment. And after treatment they have their 
laboratory result elevated to normal range. This 
event have never been reported before, and we 
refer this event to “normalization”. Moreover, 
platelet aggregation, PT, APTT, and TT all also 
showed this normalization. These result does not 
attributable to anticoagulant therapy, because all 
patient receive heparin only until the third day 
post-PCI.
According to some studies, restenosis post 
PCI in AMI patients occurs in 10-60% cases.21 
There are several proposed mechanism as to 
why these event could happen. First, mechanical 
disruption of coronary plagues by denudation of 
the arterial endothelium and subsequent exposure 
to thrombogenic matrix protein, in addition to 
underlying atherothrombotic disease, results in 
platelet activation during or after PCI.6 Second, 
it was found that ACS was associated with 
persistent platelet hyperreactivity and enhanced 
thrombin generation. In the thrombolysis in 
myocardial infarction (TIMI) 12 trials, activation 
of platelets continues even until 28 days after 
clinical stabilization post-ACS.6,10 Another study, 
the platelet reactivity in patients and recurrent 
events (PREPARE) POST-STENTING study 
also demonstrated higher posttreatment ADP-
induced aggregation in patients who suffered 
ischemic events over a 6-month period compared 
with patients without ischemic events (p=0.02).6
There is also reported that the severity of 
thrombosis was related with more severe or 
higher level of prothrombotic state as well as 
reactivity of the platelets.
Other interesting parameter are fibrinogen 
and CRP, both are acute phase markers, showed 
significant decrease before and after treatment. 
A research showed that an increase in 1 g/L of 
plasma fibrinogen was associated with a 45% 
increased risk of MI.22 CRP is an indicator 
of the severity of STEMI and the occurence 
of complications during hospitalization.23 It 
is also independently stratify patients for in-
hospital mortality risk.24 In 2005, Feinbloom 
suggested new emerging risk factors for arterial 
thrombosis, and among them are elevated CRP 
and fibrinogen.25 The 2008 JUPITER trial 
demonstrates that there was another potential 
mechanism that increases arterial trombotic 
event among healthy individuals with elevated 
hsCRP. Recently, there is also an ongoing trial 
called Cardiovascular Inflammation Reduction 
Trial (CIRT), which main purpose is to confirm 
the inflammatory hypotesis of atherothrombosis, 
which include decreasing CRP level.26 All these 
parameter changes are in contrast with other 
research which show that there are no changes 
in hemostatic profile after optimal treatments.6,11
The mechanism of normalization and 
significant decrease of fibrinogen and CRP is 
still unknown. But it may be related to how the 
stem cells works, such as paracrine effect and 
wound healing. The paracrine effect of stem 
cells has been reported to influence cardiac repair 
by protecting cardiac myocites from apoptotic 
stimuli or activate cardiac-resident stem cell to 
enhance endogenous repair capacity.17 Another 
potential mechanism is that transplanted stem 
cell may secrete a variety of growth factor 
and cytokines, which in turn alter the systemic 
hemostatic profile.27
There were 3 limitations that need to be 
addresed regarding the present study. The first 
limitation concerns the size of the sample. 
The second limitation has to do with patient’s 
baseline hemostasis profile. And lastly, the Cosphiadi Irawan                                                                                                     Acta Med Indones-Indones J Intern Med
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third limitation there were no control group. 
Therefore further study is needed to ensure the 
underlying mechanism of this event. If future 
researches are able to conclude the mechanism 
underlying normalization of hemostatic profile 
after cell-therapy injection post-AMI, it will 
help in developing new strategies in the 
treatment of cardiovascular diseases. We also 
propose the use of TEG platelet mapping in 
patients after PCI treatment, to evaluate the 
complex interaction between fibrin, thrombin, 
platelets, and coagulation factors during a 
state of hypercoagulability, which will allow 
individualized therapy.28
CONCLUSION
Our study showed that 3 months after 
injection of intracoronary peripheral blood 
stem cell, all the parameters of the hemostatic 
become normal. Moreover, 2 parameters, 
fibrinogen and CRP both showed significant 
improvement. Future prospective studies are 
needed to investigate the underlying mechanism 
of this event.
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